SCHEMBL12281641

SCHEMBL12281641

O=C1NC(=O)/C(=C/c2cc(C(F)(F)F)cc(Cl)c2N2CCOCC2)S1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ PIM2 Q9P1W9 5/20 0.49
▸ PIM1 P11309 4/20 0.49
▸ PIM3 Q86V86 2/20 0.49
▸ NR1H4 Q96RI1 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ PTPN1 P18031 5/20 0.46
▸ TTR P02766 1/20 0.44
▸ CISD1 Q9NZ45 1/20 0.44
▸ IGF1R P08069 2/20 0.44
▸ ESRRA P11474 1/20 0.43
▸ PTPN2 P17706 1/20 0.42
▸ PTPN6 P29350 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1579112 1.00 MAPT (0.51) MAPTMEN1NPC1PKMRAB9A
SCHEMBL1579116 1.00 MAPT (0.51) MAPTMEN1NPC1PKMRAB9A
SCHEMBL1580323 0.92 HPGD (0.46) MAPTMEN1NPC1PKMRAB9A
SCHEMBL1580320 0.92 HPGD (0.46) MAPTMEN1NPC1PKMRAB9A
SCHEMBL12281607 0.92 HPGD (0.46) MAPTMEN1NPC1PKMRAB9A
SCHEMBL12282079 0.91 PIM2 (0.44) MAPTMEN1NPC1PKMRAB9A
SCHEMBL1580671 0.91 PIM2 (0.44) MAPTMEN1NPC1PKMRAB9A
SCHEMBL1580670 0.91 PIM2 (0.44) MAPTMEN1NPC1PKMRAB9A
SCHEMBL12281665 0.87 PIM2 (0.49) PIM2PIM1PIM3NR1H4PTPN1
SCHEMBL1579056 0.87 PIM2 (0.49) PIM2PIM1PIM3NR1H4PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150051185-A1 Chemical Compounds 251 ASTRAZENECA AB (SE) 2015-02-19 — — US disclosed
US-20150051185-A1 Chemical Compounds 251 ASTRAZENECA AB (SE) 2015-02-19 — — US disclosed
US-8901307-B2 Chemical compounds 251 ASTRAZENECA AB (SE) 2014-12-02 — — US disclosed
US-8901307-B2 Chemical compounds 251 ASTRAZENECA AB (SE) 2014-12-02 — — US disclosed
US-20110218182-A1 CHEMICAL COMPOUNDS 251 ASTRAZENECA AB (SE) 2011-09-08 — — US disclosed
US-20110218182-A1 CHEMICAL COMPOUNDS 251 ASTRAZENECA AB (SE) 2011-09-08 — — US disclosed
WO-2010001169-A2 CHEMICAL COMPOUNDS 251 ASTRAZENECA AB (SE) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218182-A1 CHEMICAL COMPOUNDS 251 PIM1, PIM3, PIM2 MAPT 3102/4885MEN1 3123/4885NPC1 1533/4885
US-20150051185-A1 Chemical Compounds 251 PIM1, PIM3, PIM2 MAPT 3277/4885MEN1 3498/4885NPC1 1528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback